In this study, we show that patients with highly aggressive cancers of the HER2-positive and basal-like subtypes, as well as patients with luminal tumours who developed resistance to endocrine therapy, are most likely to benefit from such a therapeutic strategy, due to their higher cPLA2α expression levels. The gene discussed is ERBB2; the disease is neoplasm.